Do low hs-CRP, Lp-PLA2 activity, and myeloperoxidase suggest low current vascular inflammatory activity?

At age 52, these biomarkers can provide biologically distinct signals related to inflammation and atherosclerosis, but they do not constitute a validated composite assessment of vascular inflammation.

Clinical and prognostic evidence

• hs-CRP is the most established marker: it measures circulating CRP, a nonspecific downstream indicator of low-grade systemic inflammation. For cardiovascular risk discussions, a persistently elevated hs-CRP of ≥2 mg/L can act as a risk enhancer in selected borderline- or intermediate-risk settings; values should be interpreted when clinically stable. A value >10 mg/L warrants repeat measurement after recovery and assessment for an acute inflammatory cause.
• Lp-PLA₂ activity has a modest prospective association with coronary risk. In a 32-study individual-participant meta-analysis of 79,036 people, each 1-SD higher activity was associated with coronary heart disease risk (RR 1.10, 95% CI 1.05–1.16). Its added value beyond standard lipid-based risk assessment is limited or inconsistent.
• MPO has prognostic associations in selected coronary-disease cohorts; for example, plasma MPO >322 pmol/L predicted death, myocardial infarction, or stroke among patients undergoing elective angiography after multivariable adjustment.

Mechanistic interpretation

• IL-6 signaling through hepatocyte JAK–STAT3 increases hepatic CRP synthesis.
• Lp-PLA₂ is predominantly LDL-associated and linked to plaque-macrophage metabolism of oxidized phospholipids.
• MPO released from activated neutrophils and monocytes generates oxidants including hypochlorous acid, connecting it to leukocyte-driven oxidative injury.

Practical interpretation

• Low values across all three are directionally reassuring and plausibly support lower current inflammatory activity relevant to atherosclerosis.
• They do not rule out plaque inflammation, established atherosclerosis, or risk driven by LDL exposure and other conventional factors. MPO is assay- and specimen-dependent; neither MPO nor Lp-PLA₂ has an established routine role in contemporary cardiovascular risk assessment.

Bottom line

• Triple-low results support a cautious inference of relatively low current vascular inflammatory activity, not a validated declaration of low cardiovascular or plaque risk.